| SHORT COMMUNICATION |
|
| Year : 2022 | Volume
: 54
| Issue : 3 | Page : 221-225 |
Materiovigilance Programme of India: Current status and way forward
PK Saifuddin1, Moksh Tandon1, Vivekanandan Kalaiselvan2, Benjamin Suroy1, Vidya Pattanshetti3, Ajay Prakash1, Bikash Medhi1
1 Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India
3 Department of Pharmacology, Jawaharlal Nehru Medical College, KAHER, Belagavi, Karnataka, India
Correspondence Address:
Prof. Bikash Medhi
Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh - 160 012
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.ijp_837_21
Postmarketing vigilance system for medical devices in India is not as vigorous as of drugs. W Materiovigilance involves post marketing surveillance of adverse events caused by medical devices. As per directive of WHO, many countries including India have established their own post marketing surveillance system. In India it is known as Materiovigilance Programme of India (MvPI). This article reviews the current state of MvPI, compares it with developed countries, identifies gaps, and recommends specific measure to strengthen the existing program.
[FULL TEXT] [PDF]*
|
